MYOSCINT
LOE Approachingimciromab pentetate
BLAVIAL
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYOSCINT (Imciromab Pentetate) is a radiopharmaceutical diagnostic agent approved in 1996 for cardiac imaging. It is used to detect myocardial infarction and assess cardiac viability in patients with suspected coronary artery disease. The drug localizes to damaged myocardial tissue, enabling visualization via nuclear imaging.
LOE Approaching
As LOE approaches, this legacy diagnostic product likely operates with a minimal, maintenance-focused commercial team focused on hospital and nuclear medicine channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYOSCINT offers limited career growth opportunities given its LOE-approaching status and minimal linked job openings. Roles on this product are primarily focused on channel maintenance, reimbursement optimization, and operational efficiency rather than expansion or innovation.
Diagnostic Sales SpecialistHospital Account Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.